Search research articles
Contact Us
Filters
Showing results (161-170 of 357) with videos related to
Page
of 36
Sort By:
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
Matthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Japanese Journal of Clinical Oncology
|
March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
Hiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
Cancers
|
December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
Bertrand Tombal, Arnulf Stenzl, David Cella, et al.
JAMA Oncology
|
December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
Andrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
JAMA Oncology
|
May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
Andrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Journal of the National Cancer Institute
|
October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
Susan Halabi, Chen-Yen Lin, Eric J Small, et al.
The Prostate
|
July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
Judith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Jimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Journal for Immunotherapy of Cancer
|
January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
Aristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
Page
of 36
Search research articles
Search
Showing results (161-170 of 357) with videos related to
Sort By:
Page
of 36
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
Matthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Japanese Journal of Clinical Oncology
|
March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
Hiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
Cancers
|
December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
Bertrand Tombal, Arnulf Stenzl, David Cella, et al.
JAMA Oncology
|
December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
Andrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
JAMA Oncology
|
May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
Andrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Journal of the National Cancer Institute
|
October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
Susan Halabi, Chen-Yen Lin, Eric J Small, et al.
The Prostate
|
July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
Judith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Jimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Journal for Immunotherapy of Cancer
|
January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
Aristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
Page
of 36